Nanobiotix (NASDAQ:NBTX) Price Target Lowered to $8.00 at Guggenheim

Nanobiotix (NASDAQ:NBTX) had its price objective trimmed by Guggenheim from $12.00 to $8.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, UBS Group upgraded Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Stock Performance

Shares of NBTX stock opened at $3.27 on Friday. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51. The firm has a 50 day moving average price of $3.59 and a two-hundred day moving average price of $3.78.

Institutional Trading of Nanobiotix

A number of institutional investors have recently bought and sold shares of NBTX. Millennium Management LLC bought a new position in shares of Nanobiotix during the fourth quarter worth approximately $39,000. Jane Street Group LLC acquired a new stake in Nanobiotix during the fourth quarter worth approximately $73,000. Geode Capital Management LLC bought a new position in Nanobiotix during the 4th quarter worth $29,000. Finally, OLD Mission Capital LLC acquired a new position in Nanobiotix in the 4th quarter valued at $139,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.